Coxibs and cardiovascular risk

Coxibs and cardiovascular risk.

J Cotter and Eric Wooltorton highlight the importance of differences in cyclooxygenase 2 (COX-2) selectivity as a potential explanation for the prothrombotic effects of coxibs. However, they neglect important evidence that celecoxib might not share the same cardiovascular (CV) risk as rofecoxib. An increased thrombotic risk with celecoxib has been demonstrated only in the APC (Adenoma Preventio...

Coxibs and cardiovascular disease.

To the heart of the matter: coxibs, smoking, and cardiovascular risk.

When cyclooxygenase (COX)-2–selective inhibitors (coxibs) first entered the market about 5 years ago, the major concern with regard to cardiovascular side effects related to their potential to increase blood pressure and cause salt and water retention, in a manner similar to conventional (nonselective) nonsteroidal antiinflammatory drugs (NSAIDs). In the short time since, wariness about these s...

Arthritis medicines and cardiovascular events--"house of coxibs".

PHYSICIANS, PATIENTS, AND THE GENERAL PUBLIC ARE confronted with an acute confusional state regarding the cardiovascular safety of medicines for arthritis. Since September 30, 2004, the day that rofecoxib was precipitously withdrawn, there has hardly been a day without significant news on the general topic of cyclooxygenase 2 (COX-2) inhibitors. On December 9, 2004, the US Food and Drug Adminis...

Review of the cardiovascular safety of COXIBs compared to NSAIDS

There is no doubt that NSAIDs and COXIBS are the mainstay for managing pain and inflammation in arthritis. Overall, at therapeutically equivalent doses, both NSAIDs and COXIBs provide equivalent analgesic and anti-inflammatory efficacy. However, the gastrointestinal risk associated with NSAIDs is considerable. More recently, the cardiovascular risk associated with NSAIDs and COXIBs has become a...